Shares of Piramal Pharma surged 2.4% to ₹198.45 on the NSE after the company announced a Q2 net profit of ₹5.58 crore, a turnaround from the ₹99.2 crore loss a year earlier.
The firm’s EBITDA rose to ₹348.7 crore, up 72% YoY, and the margin expanded to 13.3%, an increase of 550 basis points from 7.8% in Q2 2025‑26—well above the 9.5% margin analysts had pegged for the sector.
Revenue jumped 28% to ₹2,617 crore, outpacing the 19% growth rate seen by the broader Indian pharma index; the CDMO arm led the charge, growing 28% and driving 72% EBITDA growth across the quarter.
Piramal’s consumer‑healthcare and complex generics units also posted solid gains—consumer sales grew 14% and e‑commerce revenue surged 32%—while the biologics pipeline added 28 molecules, lifting innovation revenue 24% in H1 FY27.
Chairperson Nandini Piramal said the company will now target FY27 revenue growth of 19‑20% and a higher EBITDA margin, citing a robust order book and disciplined cost controls. Investors are looking ahead to the June 30 FY27 results and the company’s May 2026 guidance.